Please assess the completion status of the following clinical trial:

Trial Title: Physiologic Growth Hormone Effects in HIV Lipodystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women age 18-60~* Previously diagnosed HIV infection~* Stable antiviral regimen for at least 12 weeks prior to enrollment~* Waist-to-hip ratio \>0.90 for men and \>0.85 for women~* Evidence of at least one of the following recent changes: \*increased abdominal girth,~  \*relative loss of fat in the extremities, \*relative loss of fat in the face~* Simulated peak GH response to arginine/GHRH of less than 7.5 mcg/dL~Exclusion Criteria:~* Use of Megace, anti-diabetic agents, GH, or other anabolic agents, pharmacologic glucocorticoid (prednisone \>5 mg/day or its equivalent) for 3 months prior to enrollment. Patients on a standard dose of testosterone for documented hypogonadism will be allowed to enter the protocol. Women taking standard estrogen replacement therapy for \>3 months will be allowed in the study.~* Diabetes mellitus~* Other severe chronic illness~* HgB \<9.0 g/dL, creatinine \>1.4 mg/dL, or PSA \>4 ng/mL~* Positive BHCG or failure to use appropriate birth control during study. Acceptable methods include oral contraceptives, depo provera or combined progesterone-estrogen injections, transdermal contraceptive patches, IUD's, barrier devices (condoms, diaphragms), and abstinence.~* Carpal tunnel syndrome~* Active malignancy or history of pituitary malignancy, history of colon cancer or prostate malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): recombinant human growth hormone subcutaneously once a day
- 2 (Type: PLACEBO_COMPARATOR): placebo subcutaneously once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).